Clinical Guide · PRRT Candidacy

Which patients can benefit from PRRT?

Peptide receptor radionuclide therapy works dramatically better in some patient groups than others. A sourced clinical guide to which patient types and disease scenarios benefit most — by tumour location, WHO grade, prior treatment line, and disease characteristics. Drawn from the published evidence base.

Dr. Ishita B. Sen, MDDirector & Chief, Nuclear Medicine · FMRI

Published 13 May 2026

Reviewed by Dr. Dharmender Malik

13 min read

Last reviewed by Dr. Dharmender Malik on 13 May 2026 · this article reflects the published primary literature and current clinical practice at FMRI Gurugram.

Introduction

Peptide receptor radionuclide therapy (PRRT) — most commonly Lu-177 DOTATATE / Lutathera — is approved and widely used for somatostatin-receptor-positive neuroendocrine tumours. But the published data show that benefit varies substantially across patient groups: midgut NETs respond differently from pancreatic NETs, G1 disease differently from G3, and heavily pre-treated patients differently from earlier-line. This is a sourced clinical guide to which patient types benefit most — based on the NETTER-1 and NETTER-2 phase III trials, the Brabander long-term cohort, the Vyakaranam PPGL cohort, and the major guideline frameworks (ENETS, NANETS, ESMO).

The foundational eligibility criteria

AI Overview · short answer

PRRT eligibility requires four components: (1) confirmed somatostatin receptor type 2 (SSTR2) expression on Ga-68 DOTATATE PET-CT, typically Krenning score ≥ 2 in target lesions; (2) progressive metastatic or unresectable disease; (3) adequate baseline organ function (kidneys, marrow, liver); (4) ECOG performance status capable of completing a multi-cycle course^[1]. Beyond these baseline requirements, the published data show which patient groups benefit most.

The published benchmarks for PRRT candidacy^[2]:

Krenning score ≥ 2 on Ga-68 DOTATATE PET-CT — tumour uptake equal to or greater than normal liver background.
eGFR ≥ 50 mL/min/1.73m² — adequate kidney function for amino acid co-infusion protection.
Haemoglobin ≥ 9 g/dL, platelets ≥ 100, neutrophils ≥ 1.5 — adequate marrow reserve.
Total bilirubin ≤ 3× upper limit normal; albumin ≥ 30 g/L — adequate liver function.
ECOG performance status 0-2 in most protocols.
Life expectancy generally > 6 months for the full course to be meaningful.

Midgut NETs — the strongest evidence base

The NETTER-1 phase III trial (n=229) established the strongest evidence for PRRT specifically in midgut neuroendocrine tumours. The published outcomes^[3]:

Median progression-free survival — 28.4 months on Lu-177 DOTATATE versus 8.4 months on high-dose octreotide LAR (HR 0.21; p<0.001).
Objective response rate (RECIST) — 18% versus 3%.
Long-term overall survival update (Strosberg Lancet Oncol 2021) — median OS 48.0 vs 36.3 months (HR 0.84; not statistically significant in the intent-to-treat analysis, confounded by extensive crossover).
Quality of life — significantly improved on PRRT versus control therapy^[4].

For midgut NETs specifically, PRRT is established as second-line therapy after progression on first-line somatostatin analogues. This is the strongest indication and the population in which clinicians have the most confidence about expected benefit.

Pancreatic NETs — strong evidence, different evidence base

Pancreatic NETs were not part of the NETTER-1 trial population, but the published evidence is substantial^[5]:

Cohort	n	Objective response rate	Median PFS
Sansovini (Italian cohort, pancreatic NET specifically)	60	32%	29.9 months
Brabander (Erasmus long-term, pancreatic subset)	133	55%	30 months
Kwekkeboom (older Erasmus cohort, mixed)	310	30%	—

Pancreatic NET response rates are generally higher than midgut NET response rates — likely because pancreatic NETs are more often hormonally functional and have different tumour biology. Patient selection requires confirmation that pancreatic NET is well-differentiated (G1-G2 on WHO 2019) and SSTR2-positive on imaging^[6].

Higher-grade NETs — the NETTER-2 expansion

The NETTER-2 phase III trial, published in 2024, addressed an important evidence gap by testing PRRT in higher-grade NETs^[7]:

Population — 226 patients with newly diagnosed, advanced grade 2 (Ki-67 10-20%) or grade 3 (Ki-67 21-55%) gastroenteropancreatic NET.
Comparison — Lu-177 DOTATATE + octreotide versus high-dose octreotide alone (first-line for this earlier-line population).
Primary endpoint — median PFS 22.8 months on Lu-177 DOTATATE versus 8.5 months on high-dose octreotide alone (HR 0.276; p<0.0001).
Objective response rate — 43% versus 9.3%.

NETTER-2 extended PRRT's evidence base into earlier lines and into higher-grade NETs (including a portion with Ki-67 up to 55%). For these patients — who historically faced limited systemic options — PRRT now has phase III evidence supporting first-line use in combination with octreotide.

Pheochromocytoma and paraganglioma (PPGL)

For metastatic SSTR-positive pheochromocytoma and paraganglioma, the published cohort evidence supports PRRT, although the evidence base is smaller than for GEP-NETs^[8]:

Vyakaranam Uppsala cohort (n=22) — disease control rate 86%, partial response 36%, biochemical response 32%.
Satapathy meta-analysis (11 studies, n=201) — pooled DCR 84%, ORR 29%.
Kong Melbourne cohort (n=23) — 71% disease control rate, biochemical response in most patients.

The choice between PRRT and I-131 MIBG for PPGL depends on which imaging is positive: PRRT for DOTATATE-positive disease, I-131 MIBG for MIBG-positive disease. SDHx-mutated PPGL (particularly SDHB) typically favours PRRT because of stronger DOTATATE uptake. For more on this see our PPGL PRRT guide.

Lung carcinoid tumours

Pulmonary carcinoid tumours (typical carcinoid, atypical carcinoid) are SSTR2-positive in approximately 80 percent of cases. PRRT cohort data show meaningful benefit^[9]:

Sabet German cohort (n=22 lung carcinoid) — disease control rate 73%, partial response 27%, median PFS 27 months.
Mariniello Italian cohort (n=34 lung carcinoid) — disease control rate 80%, ORR 27%, median PFS 28 months.

Patient selection requires SSTR-positive disease on Ga-68 DOTATATE PET-CT (Krenning score ≥ 2) and progressive disease on prior therapy (typically somatostatin analogues, everolimus, or chemotherapy). Small-cell lung cancer and large-cell neuroendocrine carcinoma of the lung — which are SSTR-negative on imaging in most cases — do not respond to PRRT and require platinum-based chemotherapy^[10].

Who is unlikely to benefit — patient groups where PRRT is not appropriate

Selection note · groups where PRRT does NOT help

The published evidence shows PRRT does not produce meaningful response in: (1) SSTR-negative tumours on Ga-68 DOTATATE PET-CT; (2) poorly-differentiated neuroendocrine carcinoma (NEC, Ki-67 typically > 55% with poorly-differentiated morphology) — these tumours behave more like small-cell carcinoma and require platinum-based chemotherapy; (3) patients with severely compromised marrow reserve where the modest cytopenia of PRRT would precipitate severe complications; (4) severe baseline kidney impairment (eGFR < 30 mL/min/1.73m²) where amino acid co-infusion provides insufficient protection^[11].

For these patient groups, alternative systemic therapies (platinum chemotherapy for NEC, everolimus/sunitinib for pancreatic NET, capecitabine + temozolomide for selected GEP-NETs, immunotherapy in specific biomarker contexts) are typically more appropriate. The fundamental principle: PRRT works because the radioligand specifically binds SSTR2 — without that target, the therapy cannot work.

Practical patient-selection framework

The standard multidisciplinary review at experienced centres considers the following dimensions when assessing PRRT candidacy^[12]:

Disease characteristics — tumour location, WHO 2019 grade, Ki-67 proliferation index, hormonal functional status.
Imaging — Ga-68 DOTATATE PET-CT showing Krenning score ≥ 2 and adequate target lesion distribution. Concordance between SSTR-PET and FDG-PET is informative — SSTR-positive / FDG-negative typically indicates good PRRT candidate; SSTR-positive / FDG-positive may indicate more aggressive disease^[13].
Prior therapy — first-line PRRT now an option in NETTER-2 population; second-line standard for midgut NETs after somatostatin analogue progression; salvage PRRT (re-treatment) feasible in selected responders who later progress^[14].
Comorbidities and performance status — adequate kidney/marrow reserve; ECOG 0-2; life expectancy supportive of completing a 4-cycle course.
Patient preferences — informed discussion of expected benefit, side-effect profile, and alternative options.

The bottom line — who benefits most

Midgut NETs (G1-G2) — strongest evidence base, second-line PRRT now standard of care; NETTER-1 reported 28.4 vs 8.4 month median PFS^[3].
Pancreatic NETs (G1-G2) — strong cohort evidence, generally higher response rates than midgut; Brabander pancreatic subset showed 55% ORR^[15].
Higher-grade NETs (G2 Ki-67 10-20%, G3 Ki-67 21-55%) — NETTER-2 phase III now supports first-line PRRT in this expanded population^[7].
Metastatic PPGL with DOTATATE uptake — established cohort evidence (Vyakaranam, Satapathy meta-analysis); particularly relevant for SDHx-mutated disease^[8].
Lung carcinoid (typical/atypical, SSTR-positive) — cohort evidence supports use after somatostatin analogue progression^[9].
Unlikely to benefit — SSTR-negative tumours, poorly-differentiated NEC, severely compromised marrow/kidney function.

Important

This article describes general patient-selection principles. Whether PRRT is appropriate for any individual patient requires multidisciplinary review of imaging, histology, prior treatment history, organ function, and treatment goals. Your nuclear medicine and oncology teams will integrate these factors for your specific situation.

"The most common mistake I see is patients arriving at our clinic having been told that PRRT is not an option — when in fact they have not had a proper Ga-68 DOTATATE PET-CT to confirm SSTR expression. The single most important test before any conversation about PRRT candidacy is that imaging. Without it, the question 'is PRRT right for me?' simply cannot be answered. With it, the answer is usually surprisingly clear."

Dr. Ishita B. Sen, MD · Director & Chief, Nuclear Medicine, FMRI

PRRT candidacy review · is this right for your case

If you are considering PRRT or have been told it is not an option, FMRI's nuclear medicine team can review your case — including whether you have had appropriate Ga-68 DOTATATE PET-CT imaging, tumour grading, prior treatment history, and organ function — to give you a clear answer about candidacy.

Discuss PRRT candidacy · WhatsApp +91 8800 988936

For patients & referring clinicians

Frequently asked questions

Q01 Who is a good candidate for PRRT?

The strongest candidates are patients with metastatic well-differentiated (G1-G2) neuroendocrine tumours showing somatostatin receptor expression on Ga-68 DOTATATE PET-CT (Krenning score ≥ 2). The strongest evidence base is for midgut NETs (NETTER-1: 28.4 vs 8.4 mo median PFS) and pancreatic NETs (Brabander cohort: 55% ORR in pancreatic subset) [3][15]. Higher-grade NETs (G2 Ki-67 10-20%, G3 Ki-67 21-55%) now have phase III evidence from NETTER-2 [7].

Q02 Can patients with grade 3 NETs have PRRT?

Yes — the NETTER-2 trial published in 2024 established PRRT as first-line treatment for grade 2 (Ki-67 10-20%) and grade 3 (Ki-67 21-55%) well-differentiated gastroenteropancreatic NETs, with median PFS of 22.8 vs 8.5 months (HR 0.276; p<0.0001) [7]. Note that "well-differentiated G3 NET" is distinct from "poorly-differentiated neuroendocrine carcinoma (NEC)" — the latter does not respond to PRRT and requires platinum-based chemotherapy.

Q03 What is the difference between NET and NEC for PRRT?

Well-differentiated NETs (G1/G2/G3) typically express somatostatin receptor type 2 (SSTR2), making them PRRT candidates. Poorly-differentiated neuroendocrine carcinomas (NEC) are SSTR-negative on imaging and behave like small-cell carcinoma — they do not respond to PRRT and require platinum-based chemotherapy (e.g., carboplatin + etoposide). The distinction is made by histopathology with WHO 2019 grading and confirmed by SSTR-PET imaging [11].

Q04 Can patients with pheochromocytoma have PRRT?

Yes — for metastatic SSTR-positive pheochromocytoma and paraganglioma, PRRT has cohort evidence showing 80-86% disease control rate (Vyakaranam, Satapathy meta-analysis) [8]. Selection requires DOTATATE-positive disease on Ga-68 PET-CT, and SDHx-mutated PPGL (particularly SDHB) typically favours PRRT because of stronger DOTATATE uptake. Catecholamine crisis prevention with alpha-adrenergic blockade is essential.

Q05 Does PRRT work for lung neuroendocrine tumours?

Yes — for pulmonary carcinoid tumours (typical and atypical carcinoid), which are SSTR2-positive in approximately 80% of cases, cohort evidence shows disease control rates of 73-80% and median PFS of 27-28 months after progression on somatostatin analogues [9]. Small-cell lung cancer and large-cell neuroendocrine carcinoma of the lung — typically SSTR-negative — do not respond to PRRT and require platinum-based chemotherapy [10].

Q06 What is the minimum tumour uptake needed for PRRT?

The standard threshold is Krenning score ≥ 2 on Ga-68 DOTATATE PET-CT — tumour uptake equal to or greater than normal liver background. Most protocols require Krenning score ≥ 2 in target lesions and absence of SSTR-negative measurable lesions exceeding specific size criteria [1]. Some experienced centres use semi-quantitative SUVmax thresholds (typically SUVmax ≥ 10) instead.

Q07 Can patients on dialysis have PRRT?

Generally no — PRRT requires adequate kidney function (eGFR ≥ 50 mL/min/1.73m² in most protocols) because amino acid co-infusion protects the kidneys from radiation. Severely compromised kidney function or established dialysis usually makes PRRT inappropriate. Some experienced centres have published case reports of carefully dose-adjusted PRRT in patients with eGFR 30-50, but this is not standard practice [11].

Q08 How many cycles of PRRT can a patient have?

The standard PRRT course is 4 cycles of Lu-177 DOTATATE at 7.4 GBq (200 mCi) per cycle, with 8-week intervals between cycles [1]. Patients who initially respond and later progress with maintained SSTR expression are candidates for salvage PRRT (re-treatment) — published response rates approximately 40-50% in the salvage setting (Severi et al.) [14]. The decision to re-treat weighs cumulative kidney and marrow dose against expected response benefit.

Q09 Is PRRT used before or after surgery?

PRRT is generally not used as first-line treatment for resectable disease — surgical resection remains the standard for early, localised, resectable NETs (BCLC 0/A for HCC; surgical resection for primary GEP-NET). PRRT is typically used in metastatic, unresectable, or progressive disease after first-line somatostatin analogues. For selected patients PRRT may be used neoadjuvantly to downstage borderline-resectable disease, though this is investigational [12].

Q10 What labs are needed before each PRRT cycle?

Standard pre-cycle labs include: full blood count (FBC), urea/electrolytes/creatinine, liver function tests (LFTs), serum chromogranin A and 5-HIAA (for response tracking in functional NETs). Some centres also check serum albumin, calcium, and INR. Specific functional NETs require targeted hormone testing (insulin/proinsulin, gastrin, VIP for relevant pancreatic NETs; plasma metanephrines for PPGL) [1].

Q11 Can patients with brain metastases have PRRT?

Brain metastases are uncommon in well-differentiated NETs but do occur. Brain disease is technically not a contraindication if SSTR2 is expressed, but PRRT's effect on intracranial disease is limited by the blood-brain barrier and the modest cumulative dose delivered. Brain-directed local therapy (stereotactic radiosurgery) is typically used in parallel with PRRT for systemic disease control [12]. Brain MRI is standard pre-PRRT in patients with symptoms.

Q12 Where can patients in India access PRRT?

PRRT is available at FMRI Gurugram and a small number of other Indian tertiary centres with active nuclear medicine theranostics programmes, including AIIMS New Delhi, Tata Memorial Hospital, and Apollo Hospitals. The Indian published experience is substantial — the Mittal AIIMS cohort and Bal/Yadav cohorts have contributed meaningfully to global PRRT evidence [16]. Delivery requires Ga-68 DOTATATE PET-CT for eligibility, biochemical workup, baseline organ function assessment, and multidisciplinary review.

Citations & references

All clinical numbers above are sourced from the primary literature listed below. Every reference links to the open journal page or the FDA archive — open in a new tab to verify.

[1] Bodei L, Mueller-Brand J, Baum RP, et al. The joint IAEA, EANM, and SNMMI practical guidance on PRRNT in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2013;40(5):800-816. View source ↗

[2] Hicks RJ, Kwekkeboom DJ, Krenning E, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: PRRT. Neuroendocrinology. 2017;105(3):295-309. View source ↗

[3] Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 Trial of ¹⁷⁷Lu-Dotatate for Midgut Neuroendocrine Tumors (NETTER-1). N Engl J Med. 2017;376(2):125-135. View source ↗

[4] Strosberg J, Wolin E, Chasen B, et al. Health-Related Quality of Life in Patients With Progressive Midgut NETs Treated With ¹⁷⁷Lu-Dotatate (NETTER-1). J Clin Oncol. 2018;36(25):2578-2584. View source ↗

[5] Sansovini M, Severi S, Ianniello A, et al. Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with ¹⁷⁷Lu-DOTATATE. Eur J Nucl Med Mol Imaging. 2017;44(3):490-499. View source ↗

[6] Falconi M, Eriksson B, Kaltsas G, et al. ENETS Consensus Guidelines for Pancreatic NETs. Neuroendocrinology. 2016;103(2):153-171. View source ↗

[7] Singh S, Halperin D, Myrehaug S, et al. [177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high-dose long-acting octreotide for newly diagnosed, advanced grade 2-3 GEP-NETs (NETTER-2). Lancet. 2024;403(10446):2807-2817. View source ↗

[8] Vyakaranam AR, Crona J, Norlén O, et al. Favorable outcome in PPGL treated with ¹⁷⁷Lu-DOTATATE. Cancers (Basel). 2019;11(7):909. View source ↗

[9] Sabet A, Ahmadzadehfar H, Bruhman J, et al. Efficacy of ¹⁷⁷Lu-DOTATATE for lung neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2017;44(7):1192-1199. View source ↗

[10] Caplin ME, Baudin E, Ferolla P, et al. Pulmonary neuroendocrine (carcinoid) tumors: ENETS expert consensus. Ann Oncol. 2015;26(8):1604-1620. View source ↗

[11] Carlsen EA, Fazio N, Granberg D, et al. PRRT in metastatic neuroendocrine carcinoma. Endocr Relat Cancer. 2019;26(2):227-239. View source ↗

[12] Pavel M, Öberg K, Falconi M, et al. ESMO Clinical Practice Guidelines for GEP-NEN. Ann Oncol. 2020;31(7):844-860. View source ↗

[13] Chan DL, Pavlakis N, Schembri GP, et al. Dual Somatostatin Receptor/FDG PET/CT Imaging in Metastatic Neuroendocrine Tumours. Theranostics. 2017;7(5):1149-1158. View source ↗

[14] Severi S, Sansovini M, Ianniello A, et al. Feasibility and utility of re-treatment with ¹⁷⁷Lu-DOTATATE in GEP-NENs. Eur J Nucl Med Mol Imaging. 2015;42(13):1955-1963. View source ↗

[15] Brabander T, van der Zwan WA, Teunissen JJM, et al. Long-Term Efficacy, Survival, and Safety of [¹⁷⁷Lu-DOTA⁰,Tyr³]octreotate. Clin Cancer Res. 2017;23(16):4617-4624. View source ↗

[16] Mittal BR, Kashyap R, Bhattacharya A, et al. ¹⁷⁷Lu-DOTATATE Therapy in Indian Patients with Metastatic NETs. Indian J Nucl Med. 2017;32(4):309-315. View source ↗

[17] Strosberg JR, Caplin ME, Kunz PL, et al. NETTER-1 long-term overall survival update. Lancet Oncol. 2021;22(12):1752-1763. View source ↗

[18] Kwekkeboom DJ, de Herder WW, Kam BL, et al. Treatment with the radiolabeled somatostatin analog [¹⁷⁷Lu-DOTA⁰,Tyr³]octreotate: toxicity, efficacy, survival. J Clin Oncol. 2008;26(13):2124-2130. View source ↗

[19] Bodei L, Kidd M, Paganelli G, et al. Long-term tolerability of PRRT in 807 patients. Eur J Nucl Med Mol Imaging. 2015;42(1):5-19. View source ↗

[20] Bergsma H, van Lom K, Raaijmakers MHGP, et al. Persistent Hematologic Dysfunction After PRRT. J Nucl Med. 2018;59(3):452-458. View source ↗

[21] Kong G, Grozinsky-Glasberg S, Hofman MS, et al. Efficacy of PRRT for PPGL. J Clin Endocrinol Metab. 2017;102(9):3278-3287. View source ↗

[22] Satapathy S, Mittal BR, Bhansali A. PRRT in advanced PPGL: systematic review and meta-analysis. Clin Endocrinol (Oxf). 2019;91(6):718-727. View source ↗

[23] Mariniello A, Bodei L, Tinelli C, et al. PRRT in lung carcinoid: an Italian multicenter cohort study. Eur J Nucl Med Mol Imaging. 2016;43(7):1310-1318. View source ↗

[24] Sundin A, Arnold R, Baudin E, et al. ENETS Consensus Guidelines: Imaging. Neuroendocrinology. 2017;105(3):212-244. View source ↗

[25] Rinke A, Müller HH, Schade-Brittinger C, et al. PROMID trial of octreotide LAR. J Clin Oncol. 2009;27(28):4656-4663. View source ↗

[26] Caplin ME, Pavel M, Ćwikła JB, et al. Lanreotide in metastatic enteropancreatic NETs (CLARINET). N Engl J Med. 2014;371(3):224-233. View source ↗

[27] Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic NETs (RADIANT-3). N Engl J Med. 2011;364(6):514-523. View source ↗

[28] Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for pancreatic NETs. N Engl J Med. 2011;364(6):501-513. View source ↗

[29] Strosberg JR, Halfdanarson TR, Bellizzi AM, et al. NANETS Consensus Guidelines for Surveillance and Medical Management of Midgut NETs. Pancreas. 2017;46(6):707-714. View source ↗

[30] Halfdanarson TR, Strosberg JR, Tang L, et al. NANETS 2020 Consensus on Pancreatic NETs. Pancreas. 2020;49(7):863-881. View source ↗

[31] Ballal S, Yadav MP, Bal C, et al. Concomitant ¹⁷⁷Lu-DOTATATE and capecitabine and updated outcomes of ²²⁵Ac-DOTATATE. Eur J Nucl Med Mol Imaging. 2020;47(4):934-946. View source ↗

[32] Hennrich U, Kopka K. Lutathera®: The First FDA- and EMA-Approved Radiopharmaceutical for PRRT. Pharmaceuticals (Basel). 2019;12(3):114. View source ↗

About the Author

Dr. Ishita B. Sen

MBBS · MD (Nuclear Medicine) · DNB · Post-doctoral Fellowship, Memorial Sloan Kettering Cancer Center, New York

Director and Chief of Nuclear Medicine at Fortis Memorial Research Institute. Co-founder of Theranostic Physicians Private Limited (TPPL). Two decades of clinical practice in PSMA imaging and PSMA-directed radioligand therapy, with one of the largest Indian institutional experiences in Lu-PSMA.

Full profile → All publications Book a consult

Medical disclaimer All physicians and researchers profiled on this page hold appointments at the Department of Nuclear Medicine & Molecular Imaging, Fortis Memorial Research Institute, Gurugram. Theranostic Physicians Private Limited (TPPL) is the clinical practice entity through which they consult and treat patients. Treatment outcomes vary by individual case; clinical decisions are made on the basis of complete medical records, current imaging, and a multidisciplinary review.